By Daniella Parra Promontory Therapeutics said its Phase 2 meeting with the FDA cleared the way to launch a Phase 3 registrational trial of PT-112 monotherapy for metastatic castration-resistant prostate cancer. The company is a small, NYC-based biotech that, to...

By Karen Roman ReAlta Life Sciences said it presented new clinical data from its Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD) program at the American Thoracic Society 2025 International Conference, taking place on May 18-21, in San Francisco. The...

By Daniella Parra Jeito Capital said it is leading a €132 million oversubscribed Series B funding round in Azafaros, a clinical-stage biotech company developing treatments for rare lysosomal storage disorders.  Azafaros, founded in 2018 and rooted in Dutch academic research,...

  By Exec Edge Editorial Staff In the ever-evolving healthcare landscape, choosing a specialty is a pivotal decision for medical students and aspiring healthcare professionals. Anesthesiology stands out as a compelling option for several reasons. It offers a rewarding career...

By Karen Roman Recordati said it established its three-year financial targets for 2025-2027, with expected revenue of €3.0 to €3.2 billion for 2027 and EBITDA of €1.14 to €1.225 billion. The company’s strategy is driven by organic growth, its leadership,...

By Daniella Parra Araris Biotech AG  joined a research agreement with Johnson & Johnson’s Janssen Biotech to advance the development of next-generation antibody-drug conjugates (ADCs), they said. The partnership will leverage Araris’ proprietary AraLinQ technology, a one-step, enzymatic conjugation platform...

By Karen Roman ReAlta Life Sciences said it is presenting new data from its hypoxic ischemic encephalopathy (HIE) program at the Pediatric Academic Societies Annual Meeting, taking place in Honolulu, Hawaii, from April 24-28, 2025. The findings confirm elevated inflammatory...

By Karen Roman March Biosciences said it started Phase 2 trial for MB-105, its CAR-T therapy for patients with relapsed or refractory CD5+ T-cell lymphoma. The test will take place at leading cancer centers across the country, with the first...

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. The added drugs are lisaftoclax and olverembatinib; the former used to diagnose...

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said its multi-source digital imaging system, Nanox.ARC X, received FDA 510(k) clearance for general use. The Nanox.ARC X has a simplified “plug and play” one-day installation feature and allows remote software upgrades,...